Wave Life Sciences Ltd
$ 5.87
1.03%
12 Jun - close price
- Market Cap 1,129,401,000 USD
- Current Price $ 5.87
- High / Low $ 5.97 / 5.77
- Stock P/E N/A
- Book Value 2.76
- EPS -1.05
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.53 %
- 52 Week High 21.73
- 52 Week Low 5.02
About
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development platform. The company is headquartered in Singapore.
Analyst Target Price
$21.94
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-26 | 2025-11-10 | 2025-07-30 | 2025-05-08 | 2025-03-04 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-03 |
| Reported EPS | -0.1303 | -0.3 | -0.32 | -0.31 | -0.29 | 0.17 | -0.466 | -0.25 | -0.24 | -0.15 | 0.07 | -0.2 |
| Estimated EPS | -0.3213 | -0.2704 | -0.2547 | -0.27 | -0.2556 | -0.17 | -0.28 | -0.21 | -0.21 | -0.23 | -0.18 | -0.33 |
| Surprise | 0.191 | -0.0296 | -0.0653 | -0.04 | -0.0344 | 0.34 | -0.186 | -0.04 | -0.03 | 0.08 | 0.25 | 0.13 |
| Surprise Percentage | 59.446% | -10.9467% | -25.638% | -14.8148% | -13.4585% | 200% | -66.4286% | -19.0476% | -14.2857% | 34.7826% | 138.8889% | 39.3939% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WVE
2026-06-13 15:39:43
Arrowhead Pharmaceuticals (ARWR) stock fell after Wave Life Sciences (WVE) released mixed early-stage trial data for its obesity drug WVE-007, showing a 0.9% body weight reduction versus hoped-for 2-3%. Analysts connect the disappointing Wave data to Arrowhead due to its own obesity drug pipeline (ARO-INHBE, ARO-ALK7) and the high market cap already pricing in significant obesity value. The selloff in WVE and subsequent dip in ARWR highlight investor optimism for obesity treatments and questions regarding Arrowhead's pipeline expectations.
2026-06-11 23:23:00
Wells Fargo recently raised its price target for Wave Life Sciences Ltd (NASDAQ: WVE) to $14 from $13, maintaining an Overweight rating. This decision was based on new data from the company's AATD program WVE-006, which shows potential for addressing both lung and liver AATD. Analysts anticipate a significant increase of almost 270% in Wave Life Sciences shares over the next 12 months.
2026-06-11 22:39:24
Wave Life Sciences (WVE) recently announced the failure of its obesity candidate WVE-007, coupled with institutional investor Exome Asset Management exiting its entire position. This dual setback is intensifying scrutiny on how Wave Life Sciences will manage its capital and prioritize its remaining RNA-based pipeline. The company's investment narrative now hinges on the success of its AATD and CNS assets, with updated RestorAATion 2 data for WVE-006 identified as a key near-term catalyst.
2026-06-10 23:38:54
This article highlights five stocks with significant upside potential selected by billionaire Lee Ainslie. One example provided is Wave Life Sciences Ltd, which analysts expect to see a nearly 270% increase in value over the next 12 months due to promising clinical trial data for its AATD program. The article emphasizes Ainslie's investment strategy and the rationale behind picking these high-growth potential stocks.
2026-06-08 22:40:10
Wave Life Sciences (WVE) is under scrutiny after its obesity drug candidate WVE-007 failed clinical trials and a major institutional investor exited. Despite a significant stock price drop and current trading at a discount to analyst targets, analysts still see the stock as undervalued, citing the potential of its RNA platform. However, declining revenues and widening losses present risks to this optimistic outlook.
2026-06-08 16:09:54
This article provides the transcript of Wave Life Sciences Ltd.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The content of the transcript is reserved for subscribers. Additional information on Wave Life Sciences' stock performance and recent news is also included.
